This page is unavailable
Sorry, the page you have requested either does not exist or is not available at this time.
Please return to the page you came from.
These presentations contain forward-looking statements about the Company's
plans which involve risks and uncertainties. The Company's actual results
could differ materially from those discussed in these presentations, due to
risks and uncertainties regarding the drug discovery and development
process, uncertainties in the FDA process regarding review of the Company's
NDA submission for Symlin, uncertainties regarding the Company's ongoing
clinical studies of its drug candidates including SYMLIN, AC2993, AC3056 and
AC2993 LAR, and the ability of the Company to commercialize its drug
candidates, whether through sales, distribution, marketing and/or corporate
partnering agreements, on terms acceptable to the Company or otherwise.
Additional risks and uncertainties are described in the Company's most
recently filed SEC documents, such as its Annual Report on Form 10-K for its
most recent fiscal year, under the heading "Risk Factors," and its
subsequently filed Quarterly Reports on Form 10-Q for the current fiscal